Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 106 of 116

  1. TGR-1202 + brentuximab vedotin

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  2. TH1902

    WINDTREE THERAPEUTICS INC /DE/

    Solid Tumor

    phase 1 small molecule active

    1 trial

  3. TIL

    Iovance Biotherapeutics B.V.

    Sarcoma

    phase 1 small molecule completed

    1 trial

  4. TPST-1495 twice daily

    Tempest Therapeutics

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  5. TRAME-13-25

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  6. TRIN2755

    BRIGHT MINDS BIOSCIENCES INC.

    Neoplasms

    phase 1 small molecule active

    1 trial

  7. TRU-016

    Aptevo Therapeutics

    B-cell Small Lymphocytic Lymphoma Recurrent

    phase 1 small molecule completed

    1 trial

  8. TRU-016 (anti-CD37 protein therapeutic)

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 1 small molecule completed

    1 trial

  9. TSB-9-W1

    Biotech Pharmaceutical Co.,

    Metastatic Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  10. TSC-204-A0201

    TScan Therapeutics

    Head and Neck Cancer

    phase 1 mab active

    1 trial

  11. TTI-101

    Tvardi Therapeutics

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  12. TTI-101

    Tvardi Therapeutics

    Breast Cancer

    phase 1 small molecule completed

    2 trials

  13. TTP607

    vTv Therapeutics

    Advanced Cancers

    phase 1 small molecule terminated

    1 trial

  14. TTX-MC138-NODAGA-Cu64

    Transcode Therapeutics

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  15. TVB-2640

    Sagimet Biosciences

    Solid Malignant Tumor

    phase 1 small molecule completed

    1 trial

  16. TVB-2640

    Sagimet Biosciences

    Prostatic Neoplasms, Castration-Resistant

    phase 1 small molecule active

    1 trial

  17. TYR200-101

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  18. TYRA-430

    Tyra Biosciences

    Metastatic Hepatocellular Carcinoma

    phase 1 small molecule active

    1 trial

  19. Ta-NPs (2% Tumor Volume)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Recurrent Retroperitoneal Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  20. Talabostat Mesylate

    BioXcel Therapeutics

    Cancer of Pancreas

    phase 1 small molecule terminated

    1 trial

  21. Talazoparib

    BioMarin Pharmaceutical Australia Pty Ltd

    Childhood Solid Tumors

    phase 1 small molecule completed

    1 trial

  22. Target CD7 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  23. Targeted CEA CAR-T

    Chongqing Precision Biotech Co., Ltd

    Advanced Lung Cancer

    phase 1 mab active

    4 trials

  24. Tarlatamab

    Amgen

    Neuroendocrine Prostate Cancer

    phase 1 small molecule completed

    1 trial

  25. Tarlatamab

    BEONE MEDICINES AUS PTY LTD

    Extensive Stage Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  26. Tcrx T cell

    TScan Therapeutics

    Gastric Cancer

    phase 1 mab active

    1 trial

  27. Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)

    phase 1 small molecule active

    1 trial

  28. Tepotinib

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  29. The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)

    Sinobioway Cell Therapy Co.,

    Lymphoma

    phase 1 mab active

    1 trial

  30. The TILS001 trial

    The George Institute

    advanced or metastasic triple-negative breast cancer

    phase 1 other active

    1 trial

  31. ThisCART19A

    The First People's Hospital of Lianyungang

    Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

  32. ThisCART7 cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  33. Tipifarnib

    Kura Oncology

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  34. Trastuzumab

    Hoffmann-La Roche

    Early Breast Cancer

    phase 1 small molecule completed

    1 trial

  35. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  36. Trebananib 3 mg/kg

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  37. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  38. Triprorelin for injection

    The First People's Hospital of Lianyungang

    Prostate Cancer (CRPC)

    phase 1 small molecule active

    1 trial

  39. U96

    The First People's Hospital of Lianyungang

    Relapsed or Refractory B Cell Leukemia and Lymphoma

    phase 1 small molecule active

    1 trial

  40. UB-921

    United Therapeutics Europe Ltd

    Breast Neoplasm

    phase 1 mab completed

    1 trial

  41. UHKT-CAR19-01

    The George Institute

    Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  42. UMCG-NEOLYNC-001

    Disc Medicine

    Cervical Cancer

    phase 1 other active

    1 trial

  43. UR001

    Lacuna Pharma Pty Ltd

    Non-muscle Invasive Bladder Cancer

    phase 1 other active

    1 trial

  44. UTAA09 injection

    The First People's Hospital of Lianyungang

    Recurrent or Refractory B-cell Non Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  45. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  46. Unesbulin

    PTC THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  47. VAR2-2024-CS01

    Lacuna Pharma Pty Ltd

    Multiple solid tumors including: colorectal carcinoma (CRC), pancreatic carcinoma, oesophageal or gastric carcinoma, head and neck squamous cell carcinoma (HNSCC), chondrosarcoma or osteosarcoma, bladder carcinoma, lung carcinoma and glioblastoma.

    phase 1 other active

    1 trial

  48. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.